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objective. Despite early dietary treatment phenylketonuria patients have lower IQ 
and poorer executive functions compared to healthy controls. Cognitive problems in 
phenylketonuria have often been associated with phenylalanine levels. The present 
study examined the cognitive profile and mental health in adult phenylketonuria, in 
relation to phenylalanine levels and tetrahydrobiopterin treatment.
Method. Fifty-seven early treated adult patients with phenylketonuria and 57 healthy 
matched controls (18-40 years) performed IQ-subtests and executive function-tests 
from the Amsterdam Neuropsychological Tasks. They also completed the Adult Self-
Report on mental health problems. Analyses of variance were performed to examine 
group differences.
Results. Patients with phenylketonuria had normal IQ’s although lower than controls. 
They performed poorer on working memory, inhibitory control, and sustained 
attention-tasks. Patients reported Depressive and Avoidant Personality problems 
more frequently. Specifically, patients with childhood and lifetime phenylalanine≥360 
µmol/L had poorer cognitive and mental health outcomes than controls. In a 
subset of patients, comparisons between patients on and off tetrahydrobiopterin 
showed that non-tetrahydrobiopterin users (matched for childhood, pre-treatment 
phenylalanine) were slower (on number of tasks) and reported more mental health 
problems.
Conclusions. Adult patients had lower IQ and poorer executive functions than 
controls, resembling problems observed in younger patients with phenylketonuria, 
as well as more internalizing problems. Group differences and phenylalanine-
outcome associations were smaller than those observed in younger populations. A 
subset of non-tetrahydrobiopterin users, matched for childhood phenylalanine level, 
had poorer outcome on some tests than tetrahydrobiopterin users, which might 
indicate an impact of tetrahydrobiopterin treatment beyond lowering phenylalanine. 
However, clinical relevance needs further investigation.
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InTRoduCTIon
Phenylketonuria (PKU; OMIM 261600) is an inborn error of phenylalanine (Phe) 
metabolism, characterized by an impaired conversion of Phe into tyrosine (Tyr). Left 
untreated, PKU leads to severe neurocognitive dysfunction, seizures, and behavioural 
problems. When diagnosed by neonatal screening and treated early and continuously, 
at least throughout childhood, patients develop and function (cognitively) within 
the lower normal range (Jahja, Huijbregts, de Sonneville, van der Meere, & van 
Spronsen, 2014; Smith & Knowles, 2000). On average, the intelligence quotient (IQ) 
of treated patients with PKU is approximately 8-10 points lower than that of their 
healthy counterparts (Waisbren et al., 2007). The cognitive profile of treated PKU 
is characterized by weaknesses in motor control and executive functioning, which 
are more pronounced in combination with sustained attention (Albrecht, Garbade, 
& Burgard, 2009; Christ, Huijbregts, de Sonneville, & White, 2010; Huijbregts et al., 
2003; Leuzzi et al., 2004). Extensive neuropsychological testing has particularly taken 
place among children and young adolescents with PKU.
In addition to cognitive difficulties, internalizing behaviour problems have 
frequently been reported. Findings indicated that patients with PKU experience 
problems such as depression, mood swings, anxiety, phobic reactions, and poor self-
image (Anjema et al., 2011; Arnold et al., 1998; Jahja et al., 2013; Smith & Knowles, 
2000; Weglage et al., 2000). A recent study has also found poorer social (cognitive) 
skills and functioning in adult patients with PKU compared to controls. Poorer social 
functioning was related to higher lifetime Phe (Jahja et al., 2016).
Treatment of PKU is based on blood Phe reduction by a Phe-restricted diet, 
Large Neutral Amino Acid (LNAA) supplementation, and/or pharmacological 
treatment with tetrahydrobiopterin (BH4) (Blau, van Spronsen, & Levy, 2010). BH4 
is a co-factor necessary for the phenylalanine hydroxylase (PAH) enzyme to convert 
Phe into Tyr. When there is an absence or loss of PAH activity, Phe concentrations 
increase to toxic levels for the brain. In approximately 20 to 50% of patients 
with PKU, BH4 supplementation increases Phe tolerance, probably by enzyme 
stabilization. Generally those who are BH4 responsive already have milder forms 
of PKU, caused by different types of gene mutations (Keil et al., 2013). By means of 
genotyping but also with a BH4-loading test, it can be determined whether patients 
with PKU are BH4 responsive (Anjema et al., 2013). The defined requirement for 
BH4 responsiveness is a reduction of Phe of at least 30% during 48 hours of BH4 use. 
Patients with a reduction in Phe below 20% are considered non-responders, while 
a reduction of more than 85% indicates BH4 deficiency (Anjema et al., 2013; Blau 
et al., 2010). In BH4 responsive patients, it has been shown that administration of 
BH4 results in an increase of PAH activity and a subsequent decrease of Phe levels. 
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Further benefits include an increase in Phe tolerance, which has been associated with 
improved quality of life, as adherence to the very strict diet becomes less important 
(Keil et al., 2013). There are some indications that BH4 is also beneficial for cognitive 
functioning (Burton et al., 2015; Christ, Moffitt, Peck, & White, 2013). With respect 
to the mechanisms that might underlie improvement of cognition, preliminary data 
showed that BH4 decreased prolactin concentrations. As dopamine inhibits prolactin 
production, this result was hypothesized to indicate increased dopamine availability 
in the brain (van Vliet et al., 2015), which, in turn, might improve cognitive 
functioning. There is also evidence that BH4 improves white matter integrity, but 
results regarding improvement of executive abilities are inconsistent. Whereas some 
researchers did not find such improvements (White et al., 2013), others did (Christ et 
al., 2013). Results from Christ et al. (2013) suggested that BH4 treatment leads to better 
working memory and changes in brain activation. Based on the available evidence, 
however, it is too early to conclude that BH4 improves cognition and mental health, 
and particularly, it is still unclear through which mechanisms it might do so.
It has convincingly been shown that the quality of cognitive function is 
negatively related to plasma Phe concentrations, again especially among children 
and young adolescents with PKU (Christ et al., 2010). There is also evidence 
indicating that Phe levels during childhood are more strongly related to cognitive 
functioning later in life than Phe levels at the day of neuropsychological testing, i.e. 
concurrent Phe levels (Huijbregts et al., 2002). One of the major, still outstanding 
questions in PKU concerns the upper target blood Phe concentrations to achieve 
the best outcome. The target Phe concentrations may be different for different ages, 
although it has also been claimed that target Phe concentrations should be the same 
for the whole lifespan (Camp et al., 2014). In most countries the recommended target 
range for plasma Phe levels, which are considered a surrogate marker of brain Phe 
levels, is 120 to 360 µmol/L during childhood (i.e. ≤12 years), with more lenient 
upper target levels thereafter, ranging from 600 to 1200 µmol/L (MRC, 1993).
This study aimed to investigate the cognitive profile and mental health of early 
diagnosed and treated adults with PKU compared to healthy controls. The focus 
of investigations into cognitive functioning was on cognitive domains shown to 
be deficient in early and continuously treated children and adolescents with PKU, 
i.e. IQ and executive functioning. Based on previous studies more internalizing 
mental health problems were expected. Cognitive and mental health outcomes 
were associated with Phe concentrations (concurrent, lifetime, and specifically 
in childhood). We also investigated whether, beyond lowering Phe levels, BH4 
influenced cognitive functioning and mental health.
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The PKU group consisted of 57 patients (24 males, 33 females, mean age 27.7 years 
± 6.0, range 18.7-40.0 years), all were diagnosed by neonatal screening and treated 
(through dietary protein restriction and amino acid supplements) immediately 
upon diagnosis. Neonatal screening started in the Netherlands in 1974. All patients 
paid regular follow-up visits to a Dutch university medical centre and were treated 
according to National Institutes of Health guidelines (National Institutes of Health 
Consensus Development Panel, 2001). BH4 and non-BH4 users were both included 
in this study. Twelve BH4 responsive patients used BH4 doses up to 20 mg/kg with a 
max of 1400 mg/day. A healthy control group was recruited via patients or through 
the researchers and included 57 participants (19 males, 38 females, mean age 25.7 
years ± 5.6, range 18.1-40.8 years). Four controls were family related, i.e. siblings 
or cousins, six controls were from the direct surrounding of the patient (friend, 
classmate, or partner). The PKU and control group did not differ significantly in age 
(t(112) = -1.9, p = .062), gender distribution (χ2 = 0.9, p = .338), education (χ2 = 4.3, p = 
.229), and yearly income (χ2 = 9.8, p = .080).
On the day of testing, blood samples were taken from the patients preprandially 
in order to obtain concurrent Phe levels. Historical Phe levels were provided by the 
patients’ physicians. Lifetime Phe was computed as the mean of all half-year median 
Phe levels, from birth until the day of testing. In PKU literature, it is custom to use the 
mean of half-year median Phe levels to represent lifetime Phe. During certain periods 
of life (e.g. childhood) many more samples (i.e. blood Phe determinations) are taken 
than in other periods of life (e.g. adolescence), which could bias the mean. Therefore 
the mean of half-year medians is used. Also in the same manner, Phe levels between 
0 and 12 years (i.e. childhood Phe) were calculated to improve understanding of the 
effect of Phe during this developmental stage.
The Medical Ethics Committee of the University Medical Centre Groningen 
provided national approval for the study, which is registered in the Dutch CCMO 
Register (NL38932.042.11). All participants and/or their parents signed an informed 
consent.
Instruments
This study is part of a larger Dutch multicentre study (PKU-COBESO: Jahja et 
al., 2013) focusing on cognitive, social, and behavioural sequelae of early and 
continuously treated patients with PKU in relation to (history of) metabolic control. A 
standardized testing protocol was used (Jahja et al., 2013), which took approximately 
2.5 hours to complete.
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The Block Design and Vocabulary subtests of the Wechsler Adult Intelligence 
Scale 3rd Edition (Wechsler, 1997) were used to estimate IQ. Executive functions 
(EF) were assessed using tasks from the Amsterdam Neuropsychological Tasks 
(ANT: De Sonneville, 2014). The ANT is a standardized test battery, of which the 
reliability and validity has been described extensively elsewhere (Huijbregts et al., 
2002; Rowbotham, Pit-ten Cate, Sonuga-Barke, & Huijbregts, 2009). The selected 
tasks address two core executive functions, working memory (WM) and inhibitory 
control, with one selected task (mainly measuring inhibitory control) also measuring 
sustained attention. In one task the overall number of correct responses was used, 
whereas number of errors and reaction time (RT in ms) were measured in other 
tasks. All tasks started with practice trials in order to determine whether verbal task 
instructions were understood. Participants were instructed to respond as quickly 
and as accurately as possible.
Three tasks were included to measure working memory: the Visuo-Spatial 
Sequencing task (VSS), Memory Search 2 Dimensions task (MS2D), and Feature 
Integration task (FI). These working memory tasks have multiple levels of complexity 
in different task parts. In the VSS, a fixed constellation of nine open circles is presented 
on the screen. In each trial (n = 24) between three and seven circles are highlighted 
briefly. Participants must remember which circles were highlighted as well as the 
order in which they were highlighted, and they respond in each trial by clicking the 
remembered locations in the presented order. Quality of WM is represented by the 
number of correct responses, with a further contrast between number of correctly 
identified targets (i.e. visuospatial WM) and number correct targets in the correct 
order (i.e. visuospatial and visuotemporal WM), reflecting higher-order WM skills.
The MS2D task consists of two task parts. In the first part (48 trials, with 24 
containing the target stimulus) participants have to identify one memorized target 
stimulus with two specific features (shape and colour) out of four displayed on the 
screen (e.g., a blue triangle), whereas in the second part (48 trials, with 24 containing 
a target stimulus), three different target stimuli had to be remembered (e.g., a blue 
square, a red circle, and a yellow triangle), of which one had to be present in the 
display for a yes-response (see also Rowbotham et al., 2009). A ‘yes’ response is 
given by pressing the mouse button under the index finger of the dominant hand), 
otherwise the ‘no’ button (under the index finger of the non-dominant hand) is 
pressed. The second task part thus has the higher WM demands. Number of errors 
and RT of correct responses were recorded.
In the FI task a fixed target pattern, a 3x3 matrix with three red-coloured and 
six white-coloured squares, has to be identified out of four such matrices/stimulus 
patterns displayed on the screen (80 trials, with 40 containing the target stimulus). 
The distracter stimuli (three when the target pattern was present, four when the target 
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pattern was absent) either strongly resemble the target stimulus (i.e. the “similar” 
condition) or were clearly different (the  “dissimilar” condition) (Rowbotham et al., 
2009). The similar condition requires top-down controlled search posing higher WM 
demands than the dissimilar condition. A ‘yes’ response, again consisting of a press 
of the mouse button under the index finger of the dominant hand, is required when 
the target pattern is present, a ‘no’ response when the target is absent. Again, number 
of errors and RT of correct responses were recorded and used in statistical analyses.
The Sustained Attention-Dots task (SAD) measures inhibitory control and 
sustained attention, and took about 10-12 minutes to complete (Huijbregts et al., 
2002; Leuzzi et al., 2004). It includes 600 trials, where dots are presented in random 
configurations on the computer screen: 200 trials with three dots, 200 with four dots 
and 200 with five dots. When four dots appear on the screen, participants press the 
‘yes’ button under the index finger of the dominant hand. When three or five dots 
are presented, the ‘no’ button under the index finger of the non-dominant hand must 
be pressed. When four dots appear, inhibitory control of the prepotent response is 
required, particularly when the task progresses, as the other response is required 
twice as often and progressively becomes the automatic or prepotent response. 
Auditory feedback (a beep) is given when an error is made. Inhibitory control was 
measured by the overall number of errors and Mean Series Time (MST, i.e. the mean 
RT of 50 series of 12 trials, each with three 3-, 4-, and 5-dot trials). A comparison was 
made regarding error rate and response speed (MST) during the first and last 120 
trials in order to examine performance over the course of the task, hence measuring 
sustained attention.
All tasks are self-paced. The post-response interval, i.e. the period between the 
response and next stimulus onset, is 250 ms in the SAD task and 1200 ms in the FI 
and  MS2D tasks. The valid response window, i.e. reaction times that are considered 
valid, was set at 200-6000 ms post-stimulus onset.
Mental health problems were measured by means of the Adult Self-Report 
(ASR) of the Achenbach System of Empirically Based Assessment (Achenbach 
& Rescorla, 2003). The ASR is a norm-referenced questionnaire consisting of 102 
items (with 3-point rating scales) suitable for adults. The ASR provides six DSM-IV-
oriented scales: Depressive problems, Anxiety problems, Somatic problems, Avoidant 
Personality problems, Attention Deficit/Hyperactivity problems, and Antisocial 
Personality problems. Higher scores represent more mental health problems.
data analyses
IBM SPSS Statistics 22nd version was used to conduct analyses. For comparisons 
between patients with PKU and healthy controls analyses of variance were used. 
Univariate analyses were used to compare IQ estimates, overall response speed in the 
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VSS working memory and SAD inhibition tasks, and error rate in the SAD inhibition 
task. Multivariate analyses were used to compare levels of mental health problems. 
Repeated measures analyses of variance were used to compare performance between 
patients with PKU and healthy controls across conditions in the VSS, MS2D, and FI 
working memory tasks and the SAD sustained attention. In the VSS, the within-
subjects factor was represented by “number correctly identified targets” versus 
“number correctly identified targets in the correct order”; in the MS2D this was 
represented by WM load, i.e. remembering one stimulus with two distinctive features 
in task part 1 versus remembering three stimuli with two distinctive features each 
in task part 2; in the FI the within-subjects factor was represented by WM demand, 
i.e. stimuli with dissimilar distracters versus stimuli with similar distracters; and in 
the SAD sustained attention the within-subjects factor was represented by inhibitory 
control at the beginning versus inhibitory control at the end of the task. Analyses 
were conducted with the whole PKU group and repeated without BH4 users.
Associations between Phe levels (concurrent, lifetime, and between 0 and 
12 years of age) and the cognitive and mental health outcome variables were first 
examined using Pearson one-tailed correlations. Furthermore, groups were formed, 
among the patients with PKU, according to the most commonly recommended upper 
target limits of 360 µmol/L for lifetime, concurrent, and childhood Phe and were 
compared to each other and controls using analyses of variance. In order to provide 
more insight into the effects of BH4, BH4 users and non-users, matched on (generally 
low) Phe levels during childhood and on age, were compared on cognitive profile 
and mental health. These two groups were compared to each other using the same 
analyses of variance as described above.
ResulTs
descriptive data
Concurrent, lifetime, and childhood Phe concentrations for the complete PKU group, 
for the BH4 and non-BH4 group are displayed in Table 1. Concurrent and lifetime Phe 
were significantly correlated (r = 0.57, p < .001).
Twelve out of 57 patients (21%) were BH4 responsive. The BH4 group (mean age 
23.9 years ± 4.8) was significantly younger than the non-BH4 group (mean age 28.8 
years ± 5.9): t(55) = 2.6, p = .011. Concurrent Phe (t(31) = 2.6, p = .013) and lifetime 
Phe (t(34) = 4.2, p < .001) were lower for the BH4 group (resp. 489 µmol/L ± 206 for 
concurrent Phe and 348 µmol/L ± 92 for lifetime Phe) than for the non-BH4 group 
(resp. 699 µmol/L ± 359 and 505 µmol/L ± 174). Phe concentrations in childhood 
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(0-12 years) did not significantly differ (BH4: 302 µmol/L ± 134; nonBH4: 372 µmol/L 
± 151).
Table 2 shows mean scores and standard deviations (SD) on the tasks and 
questionnaire for the PKU and control group. An overview of all statistical analyses 
is given in Table 3.
Table 1. descriptive statistics for PKu and control group
 
 
PKu  PKU nonBH4  PKU BH4  Controls
(n = 57)  (n = 45)  (n = 12)  (n = 57)
Gender (male:female) 24:33  20:25  4:8  19:38
Mean age ± SD (range) 27.7 ± 6.0 
(18.7 - 40.0)
 28.8 ± 5.9  
(19.7 - 40.0)
 23.9 ± 4.8 
(18.7 - 32.7)
 25.7 ± 5.6 
(18.1 - 40.8)
Mean Concurrent Phe ± SD (range) 655 ± 342 
(66 - 1550)
 699 ± 359  
(66 - 1550)
 489 ± 206 
(220 - 1030)
  
Mean Lifetime Phe ± SD (range)* 472 ± 172 
(223 - 1001)
 505 ± 174  
(253 - 1001)
 348 ± 92 
(223 - 527)
  
Mean Childhood Phe 0-12y ± SD (range)* 357 ± 150 
(181 - 903)
 372 ± 151  
(181 - 903)




PKu versus healthy controls: IQ, ef, and mental health
IQ. Although still within the normal range, patients with PKU had a significantly 
lower IQ (mean IQ: 100 ± 12) than the control group (mean IQ: 108 ± 11): t(107) = 3.3, 
p = .001. The observed differences were unaffected by exclusion of BH4 users: t(96) 
= 3.0, p = .004.
Working Memory. For all WM tasks, there was a strong effect of condition, i.e. 
participants performed worse in task parts with higher WM load. Both patients with 
PKU and healthy controls made more errors and were slower, with ηp²  ranging from 
0.55 to 0.91 (see Table 3) and with strong observed power around 1.00 in the more 
demanding conditions of the tasks.
In the Visuo-Spatial Sequencing task (VSS), patients with PKU were less accurate 
and slower than controls (Table 3). A significant group by condition interaction 
indicated that the difference in accuracy between patients and controls was larger 
when both location and order of target stimuli were taken into account (see Figure 1).
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Table 2. descriptive statistics measurements for PKu and control group
PKu  PKU nonBH4  PKU BH4  Controls
(n = 57)  (n = 45)  (n = 12)  (n = 57)
IQ estimate* 100 ± 12  100 ± 12  99 ± 12  108 ± 11
Working Memory        
  VSS         
  Mean N correctly identified targets 103.8 ± 1.7  103.8 ± 1.6  103.9 ± 2.1  104.4 ± 0.7
  Mean N correct in correct order 98.6 ± 5.6  98.2 ± 5.7  100.1 ± 4.8  100.7 ± 3.5
  Mean RT in ms 1057 ± 207  1090 ± 213  934 ± 125  889 ± 141
  MS2D         
  N errors Low memory load 1.7 ± 2.4  1.6 ± 2.1  2.3 ± 3.4  1.7 ± 2.2
  N errors High memory load 10.3 ± 6.6  9.9 ± 6.5  11.9 ± 7.0  9.2 ± 8.0
  Mean RT Low memory load in ms 605 ± 146  622 ± 144  542 ± 142  549 ± 80
  Mean RT High memory load in ms 2144 ± 570  2260 ± 551  1708 ± 421  1875 ± 418
  FI         
  N errors (dissimilar) 1.4 ± 2.2  1.5 ± 2.3  1.0 ± 1.7  1.3 ± 1.7
  N errors (similar) 4.5 ± 2.6  4.5 ± 2.6  4.6 ± 2.9  3.9 ± 2.6
  Mean RT dissimilar in ms 893 ± 200  919 ± 187  796 ± 225  834 ± 135
  Mean RT similar in ms 1705 ± 457  1780 ± 455  1421 ± 355  1539 ± 318
Inhibitory Control        
  SAD         
  N errors 24.6 ± 14.7  24.3 ± 15.0  25.8 ± 13.8  17.3 ± 10.3
  Mean Series Time in s 9.3 ± 1.8  9.6 ± 1.9  8.0 ± 1.1  8.7 ± 1.5
Sustained Attention        
 SAD - over the course of the task        
  Errors first 120 trials 4.0 ± 3.0  4.0 ± 2.9  4.0 ± 3.3  2.4 ± 1.7
  Errors last 120 trials 5.2 ± 3.1  5.2 ± 3.2  5.3 ± 2.7  4.1 ± 2.8
  Mean Series Time first 120 trials in s 9.1 ± 1.5  9.4 ± 1.5  7.7 ± 1.0  8.7 ± 1.5
  Mean Series Time last 120 trials in s 9.4 ± 2.2  9.7 ± 2.2  8.3 ± 1.4  8.6 ± 1.6
Mental Health        
 ASR DSM-IV scales        
  Depressive problems 5.1 ± 4.4  5.5 ± 4.5  3.6 ± 3.5  3.4 ± 3.8
  Anxiety problems 3.5 ± 2.7  3.6 ± 2.6  3.2 ± 3.1  3.2 ± 2.8
  Somatic problems 1.9 ± 1.9  1.9 ± 1.8  1.8 ± 2.3  1.4 ± 2.0
  Avoidant Personality problems 3.0 ± 2.7  3.1 ± 2.7  2.5 ± 2.5  1.8 ± 2.0
  Attention Deficit/Hyperactivity problems 4.6 ± 3.5  4.6 ± 3.7  4.6 ± 2.6  4.6 ± 3.4
  Antisocial Personality problems 2.4 ± 2.4  2.5 ± 2.5  1.8 ± 1.9  2.4 ± 2.5
* 2 IQ scores missing in nonBH4 group, 1 in BH4 group, 2 in control group
VSS: Visuo-Spatial Sequencing; MS2D: Memory Search 2 Dimensions; FI: Feature Integration; SAD: 
Sustained Attention-Dots; ASR: Adult Self-Report
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Figure 1. Repeated Measures with Working Memory task VSS: Mean number of correct 
responses ± SE for correct targets and correct targets in correct order, with significant 
effects: condition, group and condition by group interaction 
figure 1. Repeated Measures with Working Memory task Vss: Mean number of correct respons-
es ± Se for correct targets and correct targets in correct order, with significant effects: condition, 
group and condition by group interaction
In the Memory Search 2 Dimensions task (MS2D), no differences between patients 
with PKU and controls were observed regarding accuracy of task performance. 
Patients with PKU were, however, significantly slower than controls. Moreover, there 
was a group by condition interaction: results showed a greater decline in response 
speed for patients than for controls when WM load increased (see Figure 2). 
 




















Figure 2. Repeated Measures with Working Memory task MS2D: Mean reaction time ± 
SE for low and high WM load condition, with significant effects: condition, group and 
condition by group interaction 
figure 2. Repeated Measures with Working Memory task Ms2d: Mean reaction time ± se for low 
and high Wm load condition, with significant effects: condition, group and condition by group 
interaction
For the Feature Integration task (FI), again with similar accuracy, patients with PKU 
performed slower than controls and the differences between the control and PKU 
group became larger with increasing difficulty in working memory condition, i.e. 























Figure 3. Repeated Measures with Working Memory task FI: Mean reaction time ± SE 
for low and high WM load condition, with significant effects: condition, group and 
condition by group interaction 
figure 3. Repeated Measures with Working Memory task fI: Mean reaction time ± se for low 
and high Wm load condition, with significant effects: condition, group and condition by group 
interaction
Inhibitory Control. ANOVAs showed that across the entire Sustained 
Attention-Dots task (SAD), patients with PKU were less accurate and performed 
slower than controls (see Table 3).
sustained Attention. Repeated measures analyses of variance across the SAD 
revealed a significant increase of errors made at the end of the task compared to the 
start for all participants (see Table 2 and Table 3). There was no significant group by 
time effect for accuracy, indicating that the difference between patients with PKU 
and controls in accuracy of task performance did not increase with time. For speed 
of task performance, however, such an effect was observed. This interaction was 
caused by slowing of task execution in the PKU group (from MST = 9.1 sec ± 1.5 to 
a MST of 9.4 sec ± 2.2), whereas response speed of controls remained stable towards 
the end of the task (from a Mean Series Time of 8.7 sec ± 1.5 to a MST of 8.6 ± 1.6) (see 
Figure 4, right panel).
Excluding the data from the BH4 users did not change the abovementioned 
results with the ANT tasks.
mental Health. The MANOVA showed that patients with PKU reported 
significantly more Depressive problems and Avoidant Personality problems than 
controls (see Table 3). When excluding the BH4 group, results remained similar and 
effect sizes became somewhat larger (Depressive problems: ηp² = .065; Avoidant 
problems: ηp² = .067).
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Table 3. overview Repeated Measures/MAnoVAs for PKu group (n=57) and controls (n=57)
PKu versus controls
F df η²p
Working Memory: VSS     
  N of correct responses Condition1 146.2 1,112*** 0.566
  Group 7.2 1,112** 0.060
  Condition*Group 4.4 1,112* 0.038
  Reaction time Group 25.6 1,112*** 0.186
      
Working Memory: MS2D     
  N of errors Condition2 157.6 1,112*** 0.585
  Group 0.5 1,112 0.005
  Condition*Group 0.8 1,112 0.007
  Reaction time Condition2 1181.1 1,112*** 0.913
  Group 9.2 1,112** 0.076
  Condition*Group 6.5 1,112* 0.055
      
Working Memory: FI     
  N of errors Condition3 136.2 1,112*** 0.549
  Group 1.1 1,112 0.009
  Condition*Group 1.3 1,112 0.012
  Reaction time Condition3 930.1 1,112*** 0.893
  Group 4.8 1,112* 0.041
  Condition*Group 4.6 1,112* 0.039
      
Inhibitory Control: overall SAD (ANOVA)    
  Total errors  9.5 1,112** 0.078
  Mean Series Time (MST)  3.9 1,112* 0.034
Sustained Attention: over time SAD (Repeated Measures)4    
  N of errors Time 41.5 1,112*** 0.270
  Group 9.5 1,112** 0.078
  Time*Group 1.0 1,112 0.009
  Mean Series Time (MST) Time 1.2 1,112 0.010
  Group 4.4 1,112* 0.038
  Time*Group 5.0 1,112* 0.043
Mental Health: ASR (MANOVA)
   
  Depressive problems  5.2 1,110* 0.045
  Anxiety problems  0.4 1,110 0.004
  Somatic problems  1.5 1,110 0.013
  Avoidant Personality problems 6.4 1,110* 0.055
  Attention Deficit/Hyperactivity problems 0.0 1,110 0.000
  Antisocial Personality problems 0.0 1,110 0.000
*p<0.05 **p<0.01 ***p<0.001 +p<0.10
1 VSS Condition: N correctly identified targets versus N correctly identified targets in correct order
2 MS2D Condition: low (1 target) versus high (3 targets) working memory load
3 FI Condition: dissimilar versus similar target distracters














































Figure 4. Repeated Measures with Sustained Attention task SAD: Mean number of 
errors ± SE (left) and mean series time ± SE (right) for beginning and end of the task, 
with significant effects for number of errors (time and group effect) and mean series 
time (group and time by group effect) 
figure 4. Repeate  sures with sustained Attentio  task sAd: Mean number of errors ± se 
(left) and mean series time ± S  (right) for beginnin  and end of the task, with significant effects 
for number of errors (time and group effect) and mean series time (group and time by group effect)
IQ as covariate. Including IQ in the analyses of variance affected one effect 
observed for accuracy to such an extent that it became non-significant (i.e. the FI 
group by condition effect) and also two effects observed for speed of responding (i.e. 
the MS2D group by condition effect, which became a trend [F(1,106) = 3.3, p = .071, 
ηp² = .030] and the SAD group by time effect, which also became a trend [F(1,106) = 
3.0, p = .085, ηp² = .028]). After inclusion of IQ as a covariate, analyses of variance still 
showed significant group differences regarding speed of responding in the working 
memory tasks VSS (F(1,106) = 15.1, p < .001, ηp² = .124) and MS2D (F(1,106) = 4.9, p = 
.029, ηp² = .044), accuracy of inhibitory control (as measured by SAD: F(1,106) = 5.9, 
p = .017, ηp² = .053), and accuracy in sustained attention (also measured with SAD: 
F(1,106) = 5.4, p = .021, ηp² = .049). Group differences in Depressive [F(1,105) = 4.0, p 
= .048, ηp² = .037] and Avoidant Personality [F(1,105) = 4.9, p = .029, ηp² = .045] also 
remained significant after taking into account any possible IQ effects.
Correlations with concurrent Phe, lifetime Phe, and childhood Phe
IQ. For the whole PKU group, concurrent Phe was marginally (and negatively) 
related to the IQ estimate (r = -0.19, p = .081). When examining the non-BH4 group 
only, lifetime Phe was marginally (and negatively) correlated with IQ (r = -0.26, p = 
.051) and Phe between 0-12 years was significantly (and negatively) correlated with 
IQ (r = -0.30, p = .029).
Working Memory. Concurrent Phe was positively related to RT of task MS2D 
high WM load condition (r = 0.33, p = .006), and to RT of FI (low WM load condition: 
r = 0.26, p = .024; high WM load: r = 0.26, p = .026), indicating slower performance 
with higher Phe levels. For task FI, the number of errors made under high WM load 
was also positively correlated with lifetime Phe (r = 0.24, p = .039) and a trend was 
seen for childhood Phe (r = 0.22, p = .051). When excluding the BH4 group, concurrent 
Phe was significantly related to RT of the MS2D high WM load condition (r = 0.27, p 
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=.039). Lifetime Phe was still related to FI number of errors in the more demanding 
WM condition (r = 0.32, p =.016).
Inhibitory Control and sustained Attention. In the SAD task, concurrent Phe 
was significantly related to MST (r = 0.36, p = .003) and to MST at the end of the task 
(r = 0.41, p = .001): higher Phe levels were associated with slower task performance. 
These correlations remained significant when leaving out the BH4 group, although 
they became somewhat weaker.
mental Health. No significant correlations were observed between Phe 
measures and mental health outcomes, regardless of the in- or exclusion of BH4 users.
Group comparisons based on concurrent Phe, lifetime Phe, and 
childhood Phe
We also compared groups on IQ, EF, and mental health, after patients with PKU 
were split into low and high Phe groups according to the upper target level most 
frequently used in the literature and in treatment guidelines, i.e. 360 µmol/L.
IQ. With respect to IQ, patients with lifetime Phe ≥360 µmol/L (n=34) differed 
from controls [F(1,87) = 14.8, p < .001, ηp² = .145] and from patients with Phe <360 
µmol/L (n=19) [F(1,51) = 4.2, p = .046, ηp² = .076]. When concurrent Phe was used to 
create groups, again only patients with PKU with Phe ≥360 µmol/L (n=42) differed 
from controls [F(1,95) = 11.6, p = .001, ηp² = .108]. When childhood Phe was taken to 
create groups, controls differed from both PKU groups, and patients with Phe levels 
< and ≥360 µmol/L did not differ from each other.
Working memory. In the VSS task, only patients with lifetime Phe ≥360 µmol/L 
performed worse than controls (correctly identified targets: F(1,91) = 7.7, p = .007, ηp² 
= .078; correctly identified in correct order: F(1,91) = 7.4, p = .008, ηp² = .075). Also, 
when childhood Phe was used to create groups, only patients with Phe ≥360 µmol/L 
(n=21) were less accurate than controls when there was a high WM load [F(1,76) 
= 5.4, p = .023, ηp² = .066]. In the MS2D task, high WM load condition, again only 
patients with Phe ≥360 µmol/L differed from controls (lifetime: F(1,91) = 10.2, p = 
.002, ηp² = .101; concurrent: F(1,100) = 8.9, p = .004, ηp² = .082), this time with respect 
to RT. In the FI task, when higher-order WM was required (i.e. the similar condition), 
patients with childhood Phe ≥360 µmol/L made more errors than controls [F(1,76) = 
5.7, p = .020, ηp² = .069] but also compared to those with Phe <360 µmol/L [F(1,54) = 
4.1, p = .049, ηp² = .070].
Inhibitory Control and sustained Attention. In the SAD task, only patients 
with lifetime Phe ≥360 µmol/L differed from controls in overall accuracy [F(1,91) = 
9.3, p = .003, ηp² = .093], and only patients with concurrent Phe ≥360 µmol/L were 
slower than controls at the end of the task [F(1,100) = 7.1, p = .009, ηp² = .067].
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mental Health. Only patients with lifetime Phe ≥360 µmol/L had more 
Depressive [F(1,90) = 8.3, p = .005, ηp² = .084] and Avoidant personality problems 
than controls [F(1,90) = 6.2, p = .015, ηp² = .064]. Also, only patients with PKU with 
childhood Phe ≥360 µmol/L had more Depressive problems than controls [F(1,75) = 
8.4, p = .005, ηp² = .101]. They also reported more Somatic problems than both controls 
[F(1,75) = 5.0, p = .029, ηp² = .062] and patients with childhood Phe <360 µmol/L 
[F(1,52) = 5.9, p = .019, ηp² = .102].
As these results may have been influenced by the inclusion of BH4 users, the 
analyses were repeated excluding the BH4 users, but this did not result in different 
outcomes, except for one result that gave a somewhat stronger indication that Phe 
levels below 360 µmol/L during the first 12 years of life may result in better adult 
outcomes than Phe levels above that level. Patients with Phe ≥360 µmol/L (n = 19) 
differed from both controls (n = 57) [F(1,74) = 5.5, p = .021, ηp² = .070] and patients 
with Phe <360 µmol/L (n = 25) [F(1,42) = 4.8, p = .035, ηp² = .102] regarding accuracy 
when a high WM load was in place, as measured by the FI task.
Comparison low Phe-nonBH4 versus low Phe-BH4
Next comparisons were made between BH4 users (n=10) and non-users (n=25). Only 
patients with Phe concentrations in childhood <360 µmol/L were included, as BH4 
responsive patients generally already have lower Phe levels than non-responsive 
patients. Two BH4 responsive patients had Phe ≥360 µmol/L and were therefore 
excluded from these analyses. There was no significant difference in gender (χ2 = 
0.7, p = .392), childhood and concurrent Phe between the BH4 and non-BH4 group: 
respectively t(33) = 1.5, p = .14 and t(33) = 1.2, p = .24. Childhood and concurrent 
Phe was resp. 255 µmol/L ± 43 and 497 µmol/L ± 225 for the BH4 group, and for the 
non-BH4 group this was resp. 280 µmol/L ± 44 and 643 µmol/L ± 359. However, both 
groups differed in lifetime Phe (t(33) = 2.6, p = .013) and in age (t(33) = 2.1, p = .045). 
The BH4 group had a lifetime Phe of 316 µmol/L ± 61, while the non-users had a 
lifetime Phe of 405 µmol/L ± 99. And the BH4 group was younger than the non-BH4 
group (mean age 24.0 years ± 5.3 versus mean age 28.6 years ± 6.0).
The BH4 group had an IQ of 98 ± 13, while this was 103 ± 10 for the non-BH4 
users. Results showed that IQ was not significantly different between both groups: 
t(32) = 1.2, p = .24. The group of non-users was slower on the WM tasks than the 
BH4 group: VSS [F(1,33) = 6.2, p = .018, ηp² = .158], MS2D [F(1,33) = 7.7, p = .009, ηp² 
= .188], with the non-BH4 group performing more slowly in the high WM condition 
[F(1,33) = 7.6, p = .009, ηp² = .187], and FI [F(1,33) = 3.3, p = .078, ηp² = .091], again with 
the non-users being slower in the high WM condition [F(1,33) = 4.6, p = .039, ηp² = 
.122]. A similar result was observed for response speed on the SAD inhibitory control 
task [MST overall: F(1,33) = 5.4, p = .027, ηp² = .140], and MST across the SAD task, 
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i.e. sustained attention [F(1,33) = 5.9, p = .021, ηp² = .151]. When only patients were 
compared whose lifetime Phe (as well as childhood) levels were <360 µmol/L, the 
group of non-users (n = 10) reported more Depressive problems [F(1,17) = 4.4, p = 
.050, ηp² = .207] and Anxiety problems [F(1,17) = 8.2, p = .011 ηp² = .325] than the BH4 
group (n = 9).
Finally, because both groups differed in age, the BH4 group was matched to 10 
non-BH4 users, after which both groups had similar age, concurrent, childhood, and 
lifetime Phe. There were trends for information processing speed with regards to 
the VSS [F(1,18) = 3.5, p = .076, ηp² = .165], where non-BH4 users were slower, MS2D 
[F(1,18) = 3.9, p = .062, ηp² = .180], where the non-BH4 group was again slower in the 
high WM condition [F(1,18) = 5.2, p = .034, ηp² = .226], as they were in the high WM 
condition of the FI [F(1,18) = 3.4, p = .080, ηp² = .160]. Somatic problems were also 
reported more by the non-BH4 group [F(1,18) = 5.4, p = .031, ηp² = .232].
dIsCussIon
This study showed that, compared to healthy controls, adult patients with PKU had 
a slightly lower IQ, albeit in the normal range, poorer working memory, and poorer 
inhibitory control, which became more evident when combined with sustained 
attention. Patients also had more internalizing mental health problems, specifically 
depressive and avoidant personality problems. The cognitive profile observed in 
adult patients with PKU thus resembled the cognitive profile observed in children 
and young adolescents with PKU (Albrecht et al., 2009; Christ et al., 2010; Huijbregts 
et al., 2003; Leuzzi et al., 2004; Waisbren et al., 2007). Patients were mainly slower in 
responding when working memory demands were high or when inhibitory control 
was required together with sustained attention, while also often making more errors. 
Several results, concerning both accuracy and speed of task performance, were 
irrespective of IQ. This may be considered as further support for specific impairments 
in (adult) PKU. Compared to studies with younger participants (e.g. Anderson et al., 
2007; Huijbregts, de Sonneville, Licht, Sergeant, & van Spronsen, 2002; Huijbregts 
et al., 2002), effect sizes for group differences observed in the present study were 
smaller. This seems to contrast, to some extent, with the results from a meta-analyses 
by Moyle and colleagues, who reported Hedges’ g scores between 0.40-0.60 for 
group differences on several cognitive tests (including IQ and executive functioning) 
in groups of adolescents and adults (Moyle, Fox, Arthur, Bynevelt, & Burnett, 2007). 
However, it is not clear whether these strong effect sizes could be attributed to the 
adolescent group, as a distinction between adolescents and adults was not made.
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In accordance with the meta-analysis by Albrecht et al. (2009), the strength of 
associations between Phe concentrations and cognitive outcomes seems to decrease 
with age. Albrecht et al. (2009) found strong correlations in studies with children 
and adolescents with PKU, but no such associations for adult patients, whereas we 
only found few significant correlations, regardless of whether concurrent, lifetime, 
or childhood Phe levels were studied. In our study, Phe concentrations in childhood 
were negatively related to IQ, whereas concurrent and lifetime Phe levels were 
negatively related to (several aspects of) working memory task performance, and 
concurrent Phe level was negatively associated with (several aspects of) inhibitory 
control and sustained attention.
Previous studies have demonstrated that patients with lifetime Phe below 360 
µmol/L have better executive functioning (Huijbregts et al., 2002; Leuzzi et al., 2004). 
Although the results from correlational analyses were not very convincing, several 
indications were found, in accordance with previous studies (Huijbregts et al., 2002; 
Leuzzi et al., 2004), for the importance of keeping Phe levels below the upper target 
level of 360 µmol/L, which is recommended in most treatment guidelines. Overall 
group differences (on both cognitive and mental health outcomes) between patients 
with PKU and controls mainly resulted from differences between controls and 
patients with PKU who had Phe levels higher than 360 µmol/L. Patients with lifetime 
Phe levels ≥360 µmol/L most consistently differed from controls, but similar results 
were observed when groups were created based on childhood and concurrent Phe 
levels. It should be noted that patients with Phe <360 µmol/L generally did not differ 
from those with Phe levels ≥360 µmol/L. The exceptions were IQ, where patients 
with lifetime Phe ≥360 µmol/L had lower IQ scores than both controls and patients 
with Phe <360 µmol/L; one working memory task, where patients with childhood 
Phe ≥360 µmol/L had poorer scores than both controls and patients with childhood 
Phe <360 µmol/L; and internalizing mental health problems, where patients with 
childhood Phe ≥360 µmol/L reported more somatic problems than both controls and 
patients with childhood Phe <360 µmol/L.
Mental health issues, especially internalizing problems were again observed in 
our study, comparable to what has been reported in other studies (Anjema et al., 2011; 
Arnold et al., 1998; Jahja et al., 2013; Smith & Knowles, 2000; Weglage et al., 2000). 
Our patients showed more depressive and avoidant personality problems, which 
indicates avoidance of social interactions and feelings of inadequacy and inferiority. 
Mental health is strongly related to social cognition and socials skills, which have 
also been found to be suboptimal in adults with PKU (Jahja et al., 2016).
Finally, patients not using BH4, who were matched to BH4 users with respect 
to childhood (or pre-treatment) Phe concentrations, were slower than BH4 users 
on working memory, inhibitory control, sustained attention, and reported more 
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internalizing problems. The fact that these differences were observed between patients 
matched on pre-treatment Phe concentrations, makes it tempting to believe that BH4 
treatment has a positive impact on cognitive and behavioural outcomes, through 
another mechanism than lowering Phe levels. The few studies focusing on BH4 and 
cognitive outcome suggested that BH4 improves cerebral dopamine concentrations 
(which are strongly associated with cognitive functions) and white matter integrity, 
and enhances brain activation (Christ et al., 2013; van Vliet et al., 2015; White et al., 
2013). For example, Christ et al. (2013) reported associations between BH4 treatment, 
neural activation patterns and working memory performance. However, these effects 
appeared to be related to a drop in Phe levels following BH4 treatment (although no 
significant correlations between neural activation and Phe were found). There are 
also studies indicating that BH4 increases the stability of Phe (Burton, Bausell, Katz, 
Laduca, & Sullivan, 2010), which in itself seems to be related to cognitive outcomes 
(Anastasoaie, Kurzius, Forbes, & Waisbren, 2008). To date, the mechanisms through 
which BH4 treatment might improve cognition and mental health remain unclear, 
and mechanisms not directly associated with the pharmaceutical properties of 
BH4 should also be considered, particularly because BH4 responsiveness is already 
associated with milder disease. For example, psychological (or placebo) effects of 
BH4 may also be present. For example, BH4 users follow a more normal diet and/or 
feel better, have less internalizing thoughts and fewer social adjustment problems, 
than those patients on a strict diet. This might result in cross-over effects with respect 
to cognitive functioning.
Clinical relevance and limitations
It should also be noted that the observed statistically significant differences between 
the BH4 users and non-users regarding cognition and mental health may not be 
clinically relevant. When taking Cohen’s recommendations for interpreting effect 
sizes (with a partial η² of 0.01 deemed small, a partial η² of 0.06 deemed medium, and 
a partial η² of 0.14 deemed large) and power (which should be .80 or higher) (Cohen, 
1988), results for only one working memory task (MS2D) could be considered 
clinically relevant, with partial η² of 0.19, and power close to .80 (.76). For the mental 
health differences between BH4 users and non-users, only the result regarding anxiety 
could be considered clinically relevant (partial η² = .33, power = .78). Obviously, 
effect sizes and power are also largely determined by group sizes, and, whereas 
the PKU-COBESO study already has a relatively large number of participants, PKU 
remains a relatively rare disease which makes it difficult to achieve satisfactory 
power levels. Together with the results from other studies into BH4 use and cognitive 
and mental health outcomes, our results warrant further research into both effects 
and potential working mechanisms of BH4. Further to this theme, it seemed like 
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a number of our main effects indicate not only statistical significance but clinical 
relevance as well. Effect sizes were medium to large and power was satisfactory 
(around .80 or higher) for a number of overall group differences between controls 
and patients with PKU (accuracy and speed of working memory, as measured by 
different tasks, inhibitory control, and avoidant personality traits). However, clinical 
relevance became particularly evident when patients with PKU with Phe levels ≥360 
µmol/L were compared to healthy controls, with medium to large effect sizes and 
power generally well above .80 (range .77 to .97) for IQ, two out of three working 
memory tasks (speed and accuracy), inhibitory control (speed and accuracy), and 
depressive behaviour. These clinically and statistically significant group differences 
were mainly observed when groups were created based on lifetime Phe levels, with 
some effects also present when childhood or concurrent Phe levels were used for 
group formation.
Following the above, it is clear that the first limitation of this study concerns 
the small sample sizes for subgroup comparisons. A second issue is the continued 
discussion of whether or not to include IQ as a covariate in analyses of variance 
comparing patients with PKU and controls on specific cognitive abilities. As IQ scores 
are made up of a number of different cognitive abilities, including the executive 
functions measured in the present study, including IQ as a covariate may obscure 
specific impairments. Although several group differences remained significant after 
inclusion of IQ as a covariate, it is possible that if we would have administered 
the full range of IQ tests, larger decreases of group differences would have been 
observed. The issue however remains as to whether this would be a good approach, 
as it may be better to identify and target specific weaknesses within a cognitive 
profile. A third issue or limitation of the present study is that we cannot rule out 
the possibility that particularly patients who had maintained treatment and regular 
monitoring participated in this study, which may have led to an underestimation of 
effects. Future studies should try to include the full spectrum of (adult) patients with 
PKU. Finally, and this in part repeats what has already been discussed, the small 
number of participants for specific subgroup analyses, in combination with a lack of 
normative data for the neuropsychological tasks makes it difficult to determine the 
clinical relevance of the observed effects. Also, there may be other factors involved in 
influencing cognitive and mental health outcome in adulthood such as experiencing 
social support and quality of life. However, in general, there are indications that the 
adult patients with PKU still function suboptimally compared to the healthy control 
group regarding executive functioning and mental health, which is important to 
consider in future research into optimal treatment and monitoring of PKU from birth 
onwards.
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